Bourse operator decides to keep Kolon TissueGene on KOSDAQ
SEOUL– South Korea’s bourse operator on Monday decided to keep Kolon TissueGene Inc. listed on the secondary KOSDAQ after more than three years of trading suspension of the scandal-ridden drugmaker. The trading of Kolon TissueGene has been suspended since late May of 2019 after the government revoked its permit to sell the gene therapy … Read more